What is BioMarin Pharmaceuticals's cumulative cost basis?

BioMarin Pharmaceuticals (BMRN) reported cumulative cost basis of $3.07B in Q1 2026.

How has BioMarin Pharmaceuticals's cumulative cost basis changed year-over-year?

BioMarin Pharmaceuticals's cumulative cost basis increased by 73.1% year-over-year, from $1.78B to $3.07B.

What is the long-term trend for BioMarin Pharmaceuticals's cumulative cost basis?

Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's cumulative cost basis has grown at a 8.8% compound annual growth rate (CAGR), from $1.35B to $2.05B.

BioMarin Pharmaceuticals BMRN Cumulative Cost Basis

Cumulative Cost Basis at other companies

BridgeBio PharmaBBIO

——

Krystal Biotech, Inc.KRYS

——

BiogenBIIB

——

Globus MedicalGMED

——

Regeneron PharmaceuticalsREGN

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Balance sheet

See full

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Cash flow

See full

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Free cash flow$199.7M+26.7%

Valuation

See full

Market cap$10.57B-19.4%

Enterprise value$8.93B-29.3%

P/E21.1×-22.7×

P/S3.3×-1.2×

Profitability

See full

Gross margin76.5%-2.9pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin23.7%+2.5pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's cumulative cost basis?: BioMarin Pharmaceuticals (BMRN) reported cumulative cost basis of $3.07B in Q1 2026.
How has BioMarin Pharmaceuticals's cumulative cost basis changed year-over-year?: BioMarin Pharmaceuticals's cumulative cost basis increased by 73.1% year-over-year, from $1.78B to $3.07B.
What is the long-term trend for BioMarin Pharmaceuticals's cumulative cost basis?: Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's cumulative cost basis has grown at a 8.8% compound annual growth rate (CAGR), from $1.35B to $2.05B.